Acute promyelocytic leukemia

Flexipharm Austrading Announces Launch of Arsenic Trioxide Phebra (Arsenic Trioxide 1mg/ml Concentrate for Solution for Infusion)

Retrieved on: 
Monday, May 20, 2019
Chemistry, Chemical elements, Physical sciences, Hepatotoxins, Oxides, Arsenic trioxide, Sesquioxides, Acute myeloid leukemia, Arsenic, Acute promyelocytic leukemia, Trioxide, 7+3

Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.

Key Points: 
  • Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.
  • Arsenic Trioxide Phebra is a glass vial presentation of arsenic trioxide 1mg/ml concentrate solution for infusion, a NICE-recommended treatment (in combination with all-trans retinoic acid) for newly diagnosed low-intermediate risk and relapsed acute promyelocytic leukaemia or APML1,2.
  • Arsenic Trioxide Phebra is the first generic arsenic trioxide injection product to be launched in the UK and the first in a preferred vial presentation.
  • Commenting on the launch, Michael Clark, Founder and Director of Flexipharm Austrading, said: "I am delighted and proud to make Arsenic Trioxide Phebra available to the NHS.

Flexipharm Austrading Announces Launch of Arsenic Trioxide Phebra (Arsenic Trioxide 1mg/ml Concentrate for Solution for Infusion)

Retrieved on: 
Monday, May 20, 2019
Chemistry, Chemical elements, Physical sciences, Hepatotoxins, Oxides, Arsenic trioxide, Sesquioxides, Acute myeloid leukemia, Arsenic, Acute promyelocytic leukemia, Trioxide, 7+3

Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.

Key Points: 
  • Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.
  • Arsenic Trioxide Phebra is a glass vial presentation of arsenic trioxide 1mg/ml concentrate solution for infusion, a NICE-recommended treatment (in combination with all-trans retinoic acid) for newly diagnosed low-intermediate risk and relapsed acute promyelocytic leukaemia or APML1,2.
  • Arsenic Trioxide Phebra is the first generic arsenic trioxide injection product to be launched in the UK and the first in a preferred vial presentation.
  • Commenting on the launch, Michael Clark, Founder and Director of Flexipharm Austrading, said: "I am delighted and proud to make Arsenic Trioxide Phebra available to the NHS.

Northwestern University: Fighting Cancer With A Famous Poison

Retrieved on: 
Tuesday, June 26, 2018
Chemistry, Cancer, Medicine, Hepatotoxins, Antineoplastic drugs, Acute myeloid leukemia, RTT, Arsenic trioxide, Sesquioxides, Acute promyelocytic leukemia, Arsenic, 7+3

Arsenic is known more for its use as a poison than as a cancer drug.

Key Points: 
  • Arsenic is known more for its use as a poison than as a cancer drug.
  • Yet low doses of arsenic trioxide have shown a 95 percent remission rate in acute promyelocytic leukemia (APL), a type of blood cancer.
  • "So, we asked whether we could control that toxicity but still allow its destructive effect to manifest only in cancer cells."
  • Northwestern has more than 8,000 full-time undergraduate students, about 13,750 master's and doctoral students, post-doctoral fellows and professional program students.